MétaCan
Menu
Back to cohort

EFFECTS OF BLOOD PRESSURE-LOWERING ON CANCER RISK: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 300,000 PARTICIPANTS

2021· article· en· W3155925794 on OpenAlexaff
Emma Copland, Dexter Canoy, Milad Nazarzadeh, Zeinab Bidel, Mark Woodward, John Chalmers, Koon Teo, Carl J. Pepine, Barry R. Davis, Sverre E. Kjeldsen, Johan Sundström, Kazem Rahimi

Bibliographic record

VenueJournal of Hypertension · 2021
Typearticle
Languageen
FieldMedicine
TopicCancer Risks and Factors
Canadian institutionsHamilton Health SciencesMcMaster UniversityPopulation Health Research Institute
Fundersnot available
KeywordsMedicineHazard ratioInternal medicineCancerBlood pressureBody mass indexConfidence intervalObservational studyMeta-analysisPlaceboProportional hazards modelOncologyPathology

Abstract

fetched live from OpenAlex

Objective: Evidence for the effects of pharmaceutical blood pressure (BP)-lowering on cancer risk is inconsistent and based on observational data. We therefore investigated the effect of BP-lowering on the risk of cancer in a large collaborative study. Design and method: We included randomised trials participating in the Blood Pressure-Lowering Treatment Trialists’ Collaboration. Placebo-controlled trials, drug class comparison trials and trials comparing more-vs-less intensive BP-lowering that provided individual-level participant data (IPD) on cancer events were pooled. We investigated the effects of BP reduction on cancer risk by conducting one-stage IPD meta-analyses using Cox proportional hazard models, stratified by trial and accounting for competing risks. We also investigated effects stratified by age, gender, body mass index (BMI), smoking and previous antihypertensive use at baseline. Results: This analysis included 300,098 participants (42% women) from 39 trials. At baseline, the mean age of participants was 66 (standard deviation [SD] = 9), mean BMI was 28 (SD = 5), 18% were current smokers and 75% were previously on BP-lowering medication. Over a median duration of 4 years, 16,748 participants were diagnosed with cancer, and 4347 cancer deaths were reported. The hazard ratio (HR) per 5mmHg reduction in systolic BP was 1.03 (95% confidence interval [CI] 0.99–1.07) for any cancer and 1.05 (95% CI 0.98–1.12) for cancer death. We found heterogeneity in the effects of BP-lowering across age, gender, BMI and smoking groups for any cancer and cancer death, and across groups defined by previous antihypertensive use for any cancer. However, there was no evidence that BP-lowering significantly increased the risk of developing cancer in specific patient subgroups. We found no evidence for trends in increasing or decreasing risk over time for either outcome (P for trend: any cancer = 0.98, cancer death = 0.99). Conclusions: This large-scale IPD meta-analysis found no evidence that BP-lowering had an important effect on cancer risk. Although we found that BP-lowering effects differed across several patient characteristics, there was no evidence for trend in cancer risk over time. We plan to further investigate the effects of BP-lowering on site-specific cancers (breast, colorectal, kidney, lung, prostate and skin) and present these results at the meeting.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.150
Threshold uncertainty score0.464

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.290
GPT teacher head0.380
Teacher spread0.090 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of HypertensionSame topicCancer Risks and FactorsFrench-language works237,207